Jeffrey M. Holzbeierlein, MD, presented “Management of High-Grade T1 Bladder Cancer” during the 40th Annual Ralph E. Hopkins Urology Seminar on February 5th, 2020 in Jackson Hole, Wyoming.
How to cite: Holzbeierlein, Jeffrey M. “Management of High-Grade T1 Bladder Cancer” February 5th, 2020. Accessed Nov 2024. https://grandroundsinurology.com/management-of-high-grade-t1-bladder-cancer/
Management of High-Grade T1 Bladder Cancer (S1600) – Summary:
Jeffrey M. Holzbeierlein, MD, Director of the Division of Urologic Oncology at the University of Kansas Hospital and Director of Clinical Research for the Urology Department at KUMC, talks about how to manage high-grade T1 bladder cancer (HGT1BC). He discusses 5-year progression rates of HGT1BC, pathological substratification of the disease, and risk calculators to estimate patient progression. Dr. Holzbeierlein concludes by discussing enhanced cystoscopy, the value of re-resection, and the importance of bacillus Calmette-Guerin (BCG) maintenance in HGT1BC.
About The 40th Annual Ralph E. Hopkins Urology Seminar:
The Ralph E. Hopkins Urology Seminar is a multi-day meeting focused on training urologists in the latest in assessing, diagnosing, and treating urologic conditions in the clinical setting. Updates are provided on urologic cancers, stone disease, urologic reconstruction, female urology, infertility, emerging surgical techniques, and general urology. Dr. Holzbeierlein presented this lecture during the 40th iteration of the meeting on February 5th, 2020 in Jackson Hole, Wyoming.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Jeffrey M. Holzbeierlein, MD, is Director of the Division of Urologic Oncology at the University of Kansas Hospital and Director of Clinical Research for the Urology Department at the University of Kansas Medical Center. He attended Vanderbilt University and then completed his medical degree at the University of Oklahoma before returning to Vanderbilt to complete his residency in urology. After completion of his residency, Dr. Holzbeierlein spent 2 years completing his Fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center before joining the faculty at the University of Kansas Medical Center in Kansas City, Kansas, in 2002. Dr. Holzbeierlein’s research interests are focused on the androgen receptor and heat shock protein 90. He continues to have an active basic science laboratory whose work has been supported by a Department of Defense New Investigator award on which he was the Principal Investigator and by 2 R01 grants on which he is a co-investigator. His clinical research has focused on bladder cancer, including identification of clinical factors that predict response to chemotherapy and immunonutrition for patients undergoing cystectomy. He has numerous peer-reviewed publications both in basic science and clinical research. Dr. Holzbeierlein has been very involved in the South Central Section, the Society for Urologic Oncology, and the American Urological Association. He is credited with founding the Young Urologic Oncologists section of the Society of Urologic Oncology and served as its President for 2 years. He served on the Fellowship Committee of the SUO for 5 years and is the past Chair of the Fellowship Committee, and currently serves on the Executive Board for the SUO. He was awarded the Distinguished Contribution medal from the SUO in 2013 for his work on the Fellowship Committee. Within the AUA, Dr. Holzbeierlein serves on the Practice Guidelines Committee and the Public Media Committee. He was previously a member of the Section Secretaries Membership Council and was on the American Board of Urology Examination Committee from 2010-2014. In addition, Dr. Holzbeierlein served as the Kansas State Representative to the Board of the South Central Section from 2008 to 2010 and completed the AUA’s Leadership course in 2008.
